Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
Public ClinicalTrials.gov record NCT00992589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Disease (GERD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.
Study identification
- NCT ID
- NCT00992589
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 344 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Month to 11 Months
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Nov 2011 (Actual)
- Last update posted
- May 22, 2013
2009 – 2011
United States locations
- U.S. sites
- 43
- U.S. states
- 26
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Columbiana | Alabama | — | — |
| Not listed | Dothan | Alabama | — | — |
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Mobile | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Bentonville | Arkansas | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Centennial | Colorado | — | — |
| Not listed | Thornton | Colorado | — | — |
| Not listed | Maitland | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Park Ridge | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Owensboro | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Flint | Michigan | — | — |
| Not listed | Saint Paul | Minnesota | — | — |
| Not listed | Jackson | Mississippi | — | — |
| Not listed | Bridgeton | Missouri | — | — |
| Not listed | Mays Landing | New Jersey | — | — |
| Not listed | Valhalla | New Jersey | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Utica | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Youngstown | Ohio | — | — |
| Not listed | Gresham | Oregon | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Laredo | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Tomball | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Huntington | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00992589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2013 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00992589 live on ClinicalTrials.gov.